🇺🇸 FDA
Patent

US 8772495

5-lipoxygenase-activating protein inhibitor

granted A61KA61K31/444A61P

Quick answer

US patent 8772495 (5-lipoxygenase-activating protein inhibitor) held by Panmira Pharmaceuticals, LLC expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Panmira Pharmaceuticals, LLC
Grant date
Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/444, A61P, A61P1/04, A61P11/00